Evidence map›Paper›PMID 38630411›Full record

ArticleNeuroinformatics2024

Growth-Associated Protein 43 and Tensor-Based Morphometry Indices in Mild Cognitive Impairment.

Homa Seyedmirzaei, Amirhossein Salmannezhad, Hamidreza Ashayeri, Ali Shushtari, Bita Farazinia, Mohammad Mahdi Heidari, Amirali Momayezi, Sara Shaki Baher

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 1 country.

Homa SeyedmirzaeiSports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amirhossein Salmannezhad *Student Research Committee, Ghazvin University of Medical Sciences, Ghazvin, Iran.
Hamidreza Ashayeri *Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali Shushtari *Faculty of Medicine , Mazandaran University of Medical Sciences, Sari, Iran. alishoushtari1377@gmail.com.
Bita FaraziniaFaculty of Economics and Management, Shiraz Branch, Islamic Azad University, Shiraz, Iran.
Mohammad Mahdi HeidariStudent Research Committee, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Amirali MomayeziSchool of Chemical engineering, Iran University of Science and Technology, Tehran, Iran.
Sara Shaki BaherFaculty of Medicine, Tehran Branch, Islamic Azad University, Tehran, Iran.
Iran University of Science and Technology · IRIslamic Azad University Medical Branch of Tehran · IRIslamic Azad University of Shiraz · IRKashan University of Medical Sciences · IRMazandaran University of Medical Sciences · IRQazvin University of Medical Sciences · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth-associated protein 43 (GAP-43) is found in the axonal terminal of neurons in the limbic system, which is affected in people with Alzheimer's disease (AD). We assumed GAP-43 may contribute to AD progression and serve as a biomarker. So, in a two-year follow-up study, we assessed GAP-43 changes and whether they are correlated with tensor-based morphometry (TBM) findings in patients with mild cognitive impairment (MCI). We included MCI and cognitively normal (CN) people with available baseline and follow-up cerebrospinal fluid (CSF) GAP-43 and TBM findings from the ADNI database. We assessed the difference between the two groups and correlations in each group at each time point. CSF GAP-43 and TBM measures were similar in the two study groups in all time points, except for the accelerated anatomical region of interest (ROI) of CN subjects that were significantly greater than those of MCI. The only significant correlations with GAP-43 observed were those inverse correlations with accelerated and non-accelerated anatomical ROI in MCI subjects at baseline. Plus, all TBM metrics decreased significantly in all study groups during the follow-up in contrast to CSF GAP-43 levels. Our study revealed significant associations between CSF GAP-43 levels and TBM indices among people of the AD spectrum.

Indexed as

BiomarkersCognitive DysfunctionGAP-43 ProteinAgedAged, 80 and overAlzheimer DiseaseBrainDiffusion Tensor ImagingDisease ProgressionFemaleFollow-Up StudiesHumansMaleBiomarkersGAP-43 ProteinAlzheimer’s diseaseGrowth-associated protein 43Mild cognitive impairmentRegion of interestTensor-based morphometry

Identifiers

PMID38630411
OpenAlexW4394873843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.